Advice
Following an abbreviated submission
Insulin detemir is accepted for restricted use in Scotland in the treatment of children and adolescents with diabetes mellitus. The licence has been extended to include these patient groups and the restriction reflects similar advice from the Scottish Medicines Consortium (August 2004) when insulin detemir was reviewed as a new product for adult patients only.
Download detailed advice26KB (PDF)
Medicine details
- Medicine name:
- Insulin detemir (Levemir®)
- SMC ID:
- 138/04
- Indication:
- Children and adolescents with diabetes mellitus
- Pharmaceutical company
- Novo Nordisk Ltd
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 13 June 2005